Skip to main content

2023 ACCP Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
038
Development & Qualification of a Population Model of Gene Therapy for the Treatment of Hemophilia A & Comparison With FVIII Therapies

Favorite
010
Development of a Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult & Pediatric Dosing for Bispecific T Cell Engagers through Intravenous & Subcutaneous Administration

Favorite
108
Development of a Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult & Pediatric Dosing for Bispecific T Cell Engagers through Intravenous & Subcutaneous Administration

Favorite
115
Development of Electronic Patient Reported Outcome for Symptom Assessment in Severe Fever With Thrombocytopenia Syndrome Patients in Routine Clinical Practice

Favorite
088
Development, Verification & Application of Physiologically-based Pharmacokinetic Model to Evaluate the CYP3A4-mediated Drug-Drug Interactions Potential of Omaveloxolone

Favorite
026
Differential Induction Effects of Prednisone & Prednisolone on Mycophenolic Acid Intrinsic Clearance

Favorite
113
Digital Twin-Based Metaverse Clinical Trial Space: From Making Clinical Trials More Accessible to Using It as a New Clinical Trial Tool

Favorite
156
Dimethoxycurcumin Induces Global DNA Hydroxymethylation & Increases the Activity of TET Enzymes in Leukemia Cells

Favorite
007
Drug & Dietary Supplement Exposures During Pregnancy & Lactation in the United States Between 2011-2022

Favorite
105
Drug & Dietary Supplement Exposures During Pregnancy & Lactation in the United States Between 2011-2022

Favorite
051
Drug Discovery of PPAR (Peroxisome Proliferator Activated Receptor) Agonists as Promising Treatment for Alzheimer's Disease

Favorite
175
Drug-Drug Interaction (DDI) Study of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers

Favorite
030
Drug-Drug Interaction of Celecoxib With Navitoclax in Subjects With Myeloproliferative Neoplasms (MPN)

Favorite